Artes and Rhein Minapharm Continue Joint Product Development

Artes Biotechnology and Rhein Minapharm Biogenetics have jointly announced the production of a target of a therapeutic protein. The former applied its Hansenula technology platform and know-how to the generation of a therapeutic protein that was chosen by the latter – that is typically produced in E coli.

Rhein Minapharms´s target is now produced from the Hansenula polymorpha platform at higher yields and at reduced costs compared to alternative bacterial or yeast systems.

Under the terms of agreement, the former has handed over the production cell lines and has received another milestone payment.

Both companies have extended their collaboration, aiming at additional targets for Minapharm´s portfolio. Artes will be responsible for the generation of new production cell lines and will share the process research and development responsibility with the latter.